U.S. Private Equity Stake In CMIC Shows Rosy Outlook For Japan's Contract Research Market
This article was originally published in PharmAsia News
TOKYO - U.S. private equity firm Taiyo Pacific Partners secured a 5 percent stake in CMIC, Japan's largest CRO, highlighting the CRO market growth potential in Japan, despite increased focus on R&D outsourcing to China and India
You may also be interested in...
Japanese Regulators, With Drug Makers Support, Moves Toward East Asian Clinical Data Sharing And Acceptance
Japan is determined to further an initiative in promoting multi-regional clinical study data acceptance among East Asian countries, and the proposal has gained critical support from the nation's drug making industry
As Tokyo Regulators Open More To Global Clinical Trial Data, Some Japanese Drug Outfits Move West To Expand
Leaders of the India-based Veeda Clinical Research said that by placing a bridging study leg in a clinical trial program early on time lags that often exist between regulatory agencies in the West and in Asia can be further reduced. That strategy can also expedite a drug's entry into other markets and thus benefit both patients and the pharmaceutical companies behind the new products
Japan's First CRO CMIC On How ICH Affects Clinical Trials in Japan: An Interview with PharmAsia News (Part 2 of 2)
Established in 1992 as the first contract clinical trial research organization in Japan, CMIC is now one of the largest Japanese CROs and currently employs more than 2,500 employees. The company operates in Japan, the United States, South Korea, Taiwan, Singapore and China. CMIC Corporate Officer Asia Development Moriaki Akasaki sat down with PharmAsia News' Japan bureau to give his perspective on the how the International Conference on Harmonization Good Clinical Practices agreements will affect Japan and other Asian countries. Japan, for the first time is beginning to accept clinical data from China and Koreain accordance with the ICH Regional Harmonization Initiative.